Alpine Immune Sciences is a clinical-stage biopharmaceutical company that develops protein-based immunotherapies for cancer, autoimmune/inflammatory disorders, and other illnesses. Their product pipeline includes ALPN-101, ALPN-202, and ALPN-303, each designed to treat specific conditions. The business is headquartered in Seattle, Washington and has collaboration agreements with AbbVie Ireland Unlimited Company and Adaptimmune Therapeutics.